PMID- 31723824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2572-9241 (Electronic)
IS  - 2572-9241 (Linking)
VI  - 3
IP  - 2
DP  - 2019 Apr
TI  - CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope.
PG  - e185
LID - 10.1097/HS9.0000000000000185 [doi]
LID - e185
AB  - Patients with non-Hodgkin lymphomas (NHLs) resistant to standard therapies have a 
      dismal prognosis. The outcome is even poorer in patients relapsing after 
      autologous stem cell transplantation. Most of these patients do not qualify for 
      an allogeneic hematopoietic cell transplantation (HCT) due to refractory disease, 
      lack of a suitable allogeneic donor, higher age, or cumulative toxicity of 
      previous chemotherapy. Despite patients undergoing allogeneic HCT normally profit 
      from a graft-versus-lymphoma effect, overall survival in patients with NHL after 
      HCT remains short. Therefore, novel treatment modalities are urgently needed. 
      Chimeric antigen receptor (CAR)-T cells, a new class of cellular immunotherapy 
      involving ex vivo genetic modification of T cells to incorporate an engineered 
      CAR have been used in clinical trials. In the majority of studies, B cell 
      malignancies treated with CD19 targeting CAR-T cells have been analyzed. 
      Recently, results from 2 CD19 directed CAR-T cell trials with an increased 
      follow-up of patients led to Food and Drug Administration and European Medicines 
      Agency approval of tisagenlecleucel and axicabtagene ciloleucel. Common adverse 
      events (AEs) include cytokine release syndrome and neurological toxicity, which 
      may require admission to an intensive care unit, B cell aplasia and 
      hemophagocytic lymphohistiocytosis. These AEs are manageable when treated by an 
      appropriately trained team following established algorithm. In this review, we 
      summarize the results of 3 large phase II CD19 CAR-T cell trials and focus on 
      AEs. We also provide a perspective of ongoing activity in this field with the 
      intend to improve the potency of this emerging novel therapy.
CI  - Copyright (c) 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the European Hematology Association.
FAU - Hopfinger, Georg
AU  - Hopfinger G
AD  - Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical 
      University of Vienna, Vienna, Austria.
FAU - Jager, Ulrich
AU  - Jager U
AD  - Department of Internal Medicine I, Division of Hematology and Hemostaseology, 
      Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
FAU - Worel, Nina
AU  - Worel N
AD  - Department of Blood Group Serology and Transfusion Medicine, Medical University 
      of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190308
PL  - United States
TA  - Hemasphere
JT  - HemaSphere
JID - 101740619
PMC - PMC6746029
EDAT- 2019/11/15 06:00
MHDA- 2019/11/15 06:01
PMCR- 2019/03/08
CRDT- 2019/11/15 06:00
PHST- 2018/10/21 00:00 [received]
PHST- 2019/02/05 00:00 [accepted]
PHST- 2019/11/15 06:00 [entrez]
PHST- 2019/11/15 06:00 [pubmed]
PHST- 2019/11/15 06:01 [medline]
PHST- 2019/03/08 00:00 [pmc-release]
AID - HemaSphere-2018-0188 [pii]
AID - 10.1097/HS9.0000000000000185 [doi]
PST - epublish
SO  - Hemasphere. 2019 Mar 8;3(2):e185. doi: 10.1097/HS9.0000000000000185. eCollection 
      2019 Apr.